Strattera Starting Dose for Adults: 40mg Protocol Explained

The standard adult starting dose for Strattera (atomoxetine) is 40 mg once daily for the first 7 days, followed by titration to the target dose of 80 mg once daily — this is the FDA-approved protocol designed to minimize initial side effects while reaching therapeutic levels within reasonable timeframe. The 40 mg starting dose is intentionally subtherapeutic — at this dose, most patients won't experience the full ADHD treatment benefit, but they also won't be hit with the full intensity of early side effects (nausea, dry mouth, decreased appetite, fatigue, dizziness, insomnia) that are most pronounced when first introducing atomoxetine to the body. After 7 days, the body has begun to adapt, and the titration to 80 mg (the typical target adult dose) provides the therapeutic effect for ADHD symptom control. Some patients ultimately need 100 mg daily for optimal control; the maximum recommended adult dose is 100 mg daily. This careful titration protocol is one of Strattera's most important features — getting it wrong (starting too high, titrating too fast, or giving up too soon at low doses) is a common reason for treatment failure.

This guide provides comprehensive information about the adult Strattera starting dose protocol for both patients and prescribers. We address the standard starting dose rationale, why low starting matters more for atomoxetine than many other ADHD medications, week 1 detailed expectations including which side effects appear when, the titration step to 80 mg at day 7 with specific guidance, side effect watch points throughout the protocol, situations warranting staying at 40 mg longer than 7 days, what to do if titration fails (side effects too severe, no response), four-phase treatment framework (Initiation/Titration/Stabilization/Maintenance), dosing decision tree for the critical day 7 decision point, common starting dose mistakes that lead to treatment failure, CYP2D6 poor metabolizer genetic considerations affecting dose, and the bottom-line framework for successful Strattera initiation. Following this protocol properly significantly improves treatment success rates.

💊 Standard Starting Dose: 40mg

The 40 mg adult starting dose protocol:

• FDA-approved starting dose for adults with ADHD.
• Subtherapeutic at this level: Not typically sufficient for ADHD symptom control alone.
• Purpose: tolerance development to early side effects before reaching therapeutic dose.
• Duration: 7 days minimum before titration consideration.
• Once daily dosing — morning generally preferred (some patients evening if morning produces too much activation).

Dose-form considerations:

• Strattera capsules: Available in 10, 18, 25, 40, 60, 80, 100 mg strengths.
• Use 40 mg capsule once daily for starting dose.
• Can be taken with or without food — food reduces nausea.
• Capsules should not be opened — sealed for absorption properties.
• If capsule opened accidentally: Wash hands; avoid eye contact (irritant).

Why 40 mg specifically:

• Half-way to typical target dose (80 mg) — moderate exposure.
• Below most patients' threshold for severe side effects.
• Sufficient to begin physiological adaptation to atomoxetine.
• Single capsule strength — simple to dispense.
• Standardized across all adult patients (with some exceptions discussed below).

Initial prescriber assessment before starting:

• Cardiovascular history and examination.
• BP and heart rate baseline.
• Mental health history (especially mood disorders, suicidal ideation history).
• Liver function assessment if any history of liver issues.
• Other medication review for interactions (particularly CYP2D6 inhibitors like fluoxetine, paroxetine).
• MAOI exposure assessment (absolute contraindication).
• Pregnancy/breastfeeding status for women of childbearing age.

🐌 Why Start Low

The pharmacological reasoning for low starting dose:

• Atomoxetine causes initial side effects that diminish with continued use as body adapts.
• Receptor adaptation: Norepinephrine receptors gradually adjust to increased synaptic NE levels.
• Gastrointestinal adaptation: Nausea, dry mouth diminish as GI system adjusts.
• Cardiovascular adaptation: Heart rate elevation moderates over time.
• Cognitive adaptation: Initial fatigue or mental fogginess typically improves.

Why starting at target dose (80 mg) immediately would fail:

• Severe nausea: Many patients would vomit or feel too ill to continue.
• Significant fatigue: Could prevent daily functioning.
• Headache: May be severe.
• Cardiovascular reaction: More pronounced HR/BP elevation acutely.
• Treatment discontinuation: Patients commonly stop before benefits emerge.
• Real-world treatment failure: Common reason patients abandon Strattera.

Other ADHD medications by comparison:

• Stimulants (Adderall, Concerta, Vyvanse): Often started at low dose but titrated more rapidly; immediate effects allow quicker dose adjustment.
• Wellbutrin: Similar slow titration approach (150 mg → 300 mg over week).
• Intuniv: Slow titration to avoid sedation/hypotension.
• Strattera: Among most important medications to titrate slowly due to side effect profile and lack of immediate feedback.

Patient psychology factors:

• Patients want immediate effect — Strattera's delayed therapeutic onset (4-6 weeks) frustrates many.
• Side effects appear before benefits — discouraging without proper expectations.
• Education about timeline crucial — patient must understand the protocol.
• Adherence challenges when feeling worse without yet feeling better.
• Prescriber relationship matters — frequent check-ins early reduce discontinuation.

📅 Week 1: What to Expect

Detailed week 1 expectations on 40 mg:

Day 1 (first dose):

• Take with food to reduce nausea.
• Morning dose generally preferred.
• Side effects may begin within hours: Nausea, dry mouth most common.
• Mild headache possible.
• Fatigue may emerge later in day.
• Hydrate well.
• No expected ADHD benefit yet.

Days 2-3:

• Continue 40 mg with food.
• Nausea may peak or begin diminishing.
• Fatigue may be most pronounced.
• Sleep may be affected: Either insomnia or sedation.
• Mild GI symptoms common: Decreased appetite, mild stomach discomfort.
• Avoid alcohol during initial period.

Days 4-5:

• Most patients notice nausea improving.
• Headache typically diminished.
• Fatigue may persist or improve.
• Sleep patterns may stabilize.
• Subtle calming or reduced impulsivity in some patients — early hints of effect.
• Continue with food.

Days 6-7:

• Side effects substantially reduced for most patients.
• Body adapted to 40 mg level.
• Decision point approaching: Titrate to 80 mg or continue at 40 mg.
• Patient assessment of tolerance.
• Prescriber contact for dose adjustment discussion (often phone or quick visit).

Common Week 1 challenges:

• Severe nausea: Some patients can't tolerate; consider taking with larger meal, antiemetic if necessary.
• Persistent fatigue: Most improves but some patients struggle.
• Loss of motivation: Could be Strattera effect or expectation mismatch.
• Sleep disruption: Move dose to morning if evening dosing causing insomnia.
• Cognitive fog: Often improves; can be initial complaint.

Side effect management strategies:

• Take with substantial meal — not just snack.
• Stay well hydrated.
• Avoid alcohol during initiation.
• Eat smaller meals more frequently if appetite decreased.
• Sugar-free gum or candy for dry mouth.
• Track symptoms in diary for prescriber discussion.
• Don't stop suddenly — contact prescriber if needing to discontinue.

📈 Titration to 80mg at Day 7

The titration step on day 7:

• Day 7 reassessment: Patient + prescriber evaluate tolerance.
• If tolerable side effects: Increase to 80 mg starting day 8.
• Switch to 80 mg capsule: Single capsule once daily continues.
• Same time of day as before (morning typically).
• Continue taking with food.

What to expect after dose increase:

• Side effects may briefly intensify: Days 8-10 may have transient symptom return.
• Nausea may briefly reappear: Usually milder than initial exposure.
• Body adapts within 5-7 days to new dose level.
• Subtle ADHD benefits may emerge: Improved focus, reduced impulsivity, better task completion.
• Full therapeutic effect still takes 4-6 weeks total from starting.

Why titrate after just 7 days:

• Initial side effects mostly resolved by day 7 for most patients.
• Further delay risks discontinuation without therapeutic benefit.
• Standard protocol effective for most adults.
• Therapeutic dose needed for ADHD response.
• Cost-effective approach avoiding extended subtherapeutic period.

Variations in standard titration:

• Some prescribers wait longer (10-14 days) at 40 mg for cautious patients.
• Some titrate to 60 mg intermediate step before 80 mg in sensitive patients.
• Direct titration to target in straightforward patients.
• Individualized approach based on patient response.

Specific patient communication:

• "You're moving to your therapeutic dose" — patient understands progression.
• "Side effects may briefly return" — expectation setting.
• "This is when benefits start emerging" — motivation.
• "4-6 weeks for full effect" — patience required.
• "Contact me with concerns" — accessible follow-up.

⚠️ Side Effect Watch Points

Side effects by frequency and timing:

Very common early side effects (>10% patients):

• Nausea: Most patients; peaks days 2-4, resolves by day 7-14.
• Dry mouth: Common throughout treatment.
• Decreased appetite: Begins early; may persist.
• Fatigue: Common initial; improves for most.
• Dizziness: Especially with position changes early in treatment.
• Insomnia: Some patients; usually with evening dosing.
• Headache: Common initial; resolves.

Common (1-10%):

• Constipation.
• Erectile dysfunction in men.
• Decreased libido.
• Sweating.
• Urinary hesitation.
• Heart rate increase 5-10 bpm.
• BP increase 1-3 mmHg.
• Weight loss.
• Mood changes.

Less common but important (<1%):

• Liver function abnormalities: Rare but serious; jaundice, dark urine warrant immediate attention.
• Suicidal ideation: FDA Black Box warning; particularly in adolescents/young adults.
• Severe cardiovascular events: Rare in healthy patients.
• Psychotic symptoms: Rare; particularly in patients with mood disorders.
• Severe allergic reactions.

Symptoms requiring immediate prescriber contact:

• Severe nausea/vomiting preventing intake.
• Severe headache or dizziness.
• Chest pain or severe palpitations.
• Jaundice (yellowing skin/eyes) or dark urine.
• Suicidal thoughts or severe mood changes.
• Severe abdominal pain.
• Allergic reaction (rash, swelling, breathing difficulty).
• Confusion or hallucinations.

Side effect management approach:

• Track side effects in diary with timing and severity.
• Distinguish tolerable from intolerable.
• Use management strategies: Food, hydration, timing adjustments.
• Contact prescriber for severe or persistent symptoms.
• Don't stop suddenly — taper if discontinuation needed.
• Patience with adaptation: Most early side effects resolve.

⏸️ When to Stay at 40mg Longer

Situations warranting extended 40 mg duration:

• Severe initial side effects: Significant nausea, fatigue, or other symptoms not resolving by day 7.
• Particularly sensitive patients: History of medication sensitivity, slow metabolizers.
• CYP2D6 poor metabolizers: Lower effective dose may be needed (genetic testing relevant).
• Patients on CYP2D6 inhibitors: Fluoxetine, paroxetine, quinidine, bupropion raise atomoxetine levels.
• Liver impairment: Dose adjustment per hepatic function.
• Cardiovascular concerns: Slower titration with monitoring.
• Older adults (less common but possible): More cautious titration.
• Underweight patients: Lower per-kg dose may suffice.

How long to stay at 40 mg:

• Additional 7 days (total 2 weeks): Common extension for sensitive patients.
• Total 3-4 weeks at 40 mg if persistent side effects on titration attempts.
• Indefinite 40 mg: Some patients achieve ADHD benefit at this dose; rare but possible.
• Reassess weekly during extended low-dose phase.

Decision factors:

• Side effect severity and impact on function.
• Whether any ADHD benefit observed at 40 mg.
• Patient preference and tolerance.
• Prescriber clinical judgment.
• Patient ability to function during titration.

Alternative dose reductions:

• Some prescribers use 18 mg or 25 mg as starting dose for very sensitive patients.
• 10 mg starting dose for extremely sensitive patients (less common in adults).
• Lower doses than FDA-approved starting sometimes used clinically.
• Pediatric dosing applied to small adults (1.2 mg/kg/day target).

❌ Failed Titration: What Next

If titration to 80 mg fails:

Side effects too severe at 80 mg:

• Return to 40 mg for additional 1-2 weeks adaptation.
• Try slower titration: 40 mg → 60 mg → 80 mg over 3-4 weeks.
• Use intermediate doses: 60 mg may provide therapeutic effect with better tolerability.
• Address specific side effects: Antiemetics for nausea, sleep hygiene for insomnia.
• Consider alternative ADHD medications if Strattera not tolerable.

No therapeutic response at 80 mg after 4-6 weeks:

• Confirm adherence: Patient actually taking daily?
• Confirm dose: 80 mg adequate for body size?
• Consider increase to 100 mg: Maximum FDA-approved dose for adults.
• Wait additional 2-4 weeks at 100 mg for full assessment.
• If still no response: Consider Strattera ineffective; discuss alternatives.

Alternative ADHD medications if Strattera fails:

• Stimulants (Adderall, Vyvanse, Concerta, Ritalin): Different mechanism; often effective if Strattera fails.
• Wellbutrin (bupropion): Off-label for ADHD; different mechanism.
• Intuniv (guanfacine): Alpha-2 agonist; different mechanism.
• Qelbree (viloxazine): Newer non-stimulant similar to Strattera.
• Modafinil: Off-label for ADHD; different profile.

Combination approaches:

• Strattera + stimulant: Sometimes combined for synergistic effect.
• Strattera + Intuniv: Different non-stimulant combinations.
• Specialist consultation for complex cases.

When to refer to specialist:

• Persistent symptom control issues despite multiple medication trials.
• Significant comorbidities complicating treatment.
• Severe side effects requiring complex management.
• Adult-onset ADHD diagnostic questions.
• Suspected ADHD vs other conditions requiring evaluation.

📊 Treatment Phase Framework

Four-phase Strattera treatment framework:

Phase 1 — "Initiation" (Days 1-7). 40 mg daily starting dose. Goal: side effect adaptation. Patient education critical. Expect: nausea, fatigue, possible headache. Side effects typically peak days 2-4, improve by day 7. No expected ADHD benefit. Track symptoms in diary. Prescriber contact for severe symptoms.

Phase 2 — "Titration" (Days 8-28). Dose increase to 80 mg starting day 8. Goal: reach therapeutic level. Brief side effect re-emergence days 8-10 then resolution. Subtle ADHD benefits may emerge weeks 2-3. Continue monitoring. Reassessment at week 4. May increase to 100 mg if insufficient response.

Phase 3 — "Stabilization" (Weeks 4-12). Maintain effective dose (typically 80 mg, sometimes 100 mg). Goal: maximize therapeutic benefit. Full ADHD response assessment by weeks 6-8. Side effects substantially diminished. Lifestyle optimization (exercise, sleep, nutrition). Treatment plan refinement.

Phase 4 — "Maintenance" (Months 3+). Long-term effective dose. Goal: sustained ADHD symptom control. Regular monitoring (every 3-6 months typically). Side effect monitoring. Adjust dose if needed over time. Address comorbidities. Consider whether continued treatment needed (some adults eventually discontinue successfully; others continue indefinitely).

Transitions between phases:

• Phase 1 → 2: Dose increase at day 7-8.
• Phase 2 → 3: Full therapeutic dose stabilization around week 4.
• Phase 3 → 4: Once optimal response achieved (weeks 6-12).
• Each phase requires different monitoring focus.

🌳 Dosing Decision Tree at Day 7

Day 7 decision framework:

Question 1: Are side effects tolerable?

• Yes (mild, manageable): → Proceed to titration consideration (Question 2).
• No (severe, functional impairment): → Stay at 40 mg another 7 days; reassess.
• Severe and not improving: → Consider discontinuation; discuss alternatives with prescriber.

Question 2: Any signs of ADHD benefit at 40 mg?

• Yes (subtle improvements): → Proceed to 80 mg titration (full effect expected).
• No (no observable benefit): → Still proceed to 80 mg titration (40 mg subtherapeutic for most).
• Significant benefit at 40 mg: → Rare; consider whether 40 mg sufficient (uncommon).

Question 3: Special circumstances?

• CYP2D6 inhibitor concurrent: → Lower target dose (40 mg may be effective dose).
• Known CYP2D6 poor metabolizer: → Lower dose; slower titration.
• Liver impairment: → Dose adjustment per hepatic function.
• Significant comorbidities: → Individualized approach.

Action steps for each decision:

• Proceed to 80 mg: Switch to 80 mg capsule day 8; expect brief side effect re-emergence then improvement; 4-6 week full effect timeline.
• Stay at 40 mg longer: Continue 40 mg another 7 days; daily symptom tracking; reassess at end of extended period.
• Discontinue: Don't stop suddenly without prescriber guidance; usually 1-2 week taper for adults.
• Lower target dose: Per specific circumstances; coordinated care.

Common day 7 patient communications:

• "How were the first 7 days?" — open-ended assessment.
• "What side effects did you have, and how severe?"
• "Are they improving?"
• "Have you noticed any changes — calmer, more focused, easier to start tasks?"
• "How is your sleep, appetite, mood?"
• "Are you ready to try 80 mg, or should we stay here longer?"

🚫 Common Starting Dose Mistakes

Mistakes that lead to Strattera treatment failure:

Mistake 1 — Starting too high:

• Starting at 80 mg directly: Severe initial side effects; patient discontinues.
• Skipping 40 mg starting dose: Misses tolerance development phase.
• Result: High discontinuation rate; patient labeled "couldn't tolerate Strattera."
• Fix: Always start at 40 mg; titrate as protocol.

Mistake 2 — Titrating too quickly:

• Increasing dose before day 7: Body hasn't adapted to initial dose.
• Going to 100 mg immediately at day 7: Skips 80 mg therapeutic assessment.
• Result: Compounded side effects.
• Fix: Follow protocol pacing.

Mistake 3 — Giving up too early:

• Discontinuing during week 1 side effects.
• Stopping before week 4 therapeutic assessment.
• Not waiting full 4-6 weeks for benefits.
• Result: Premature treatment failure; patient never got to therapeutic effect.
• Fix: Patient education about timeline; survive initial side effects.

Mistake 4 — Inadequate dose for body size:

• 80 mg for very large patients may be subtherapeutic.
• Not increasing to 100 mg when 80 mg insufficient.
• Pediatric dosing approach (1.2 mg/kg/day) sometimes useful in adults.
• Result: Treatment appears to "not work" but actually inadequate dose.
• Fix: Body weight-based assessment; willingness to use 100 mg max.

Mistake 5 — Ignoring drug interactions:

• Starting Strattera in patients on fluoxetine/paroxetine at standard dose: serum levels too high.
• Missing MAOI exposure (absolute contraindication — washout required).
• Result: Excessive side effects or contraindicated combination.
• Fix: Thorough medication review before starting.

Mistake 6 — Wrong dose timing:

• Evening dosing causing insomnia.
• Morning dosing causing daytime activation issues.
• Result: Suboptimal tolerance; consider switching timing.
• Fix: Individualize timing based on patient response.

Mistake 7 — Lack of follow-up:

• Prescriber not checking in during initiation.
• Patient feels abandoned during difficult side effect period.
• Result: Discontinuation without prescriber awareness.
• Fix: Phone check-in at day 3, day 7; office visit week 4.

🧬 CYP2D6 Poor Metabolizer Considerations

CYP2D6 genetic considerations:

• CYP2D6 enzyme metabolizes atomoxetine — genetic variation affects clearance.
• Phenotypes: Poor metabolizer (PM), intermediate metabolizer (IM), extensive metabolizer (EM — normal), ultra-rapid metabolizer (UM).
• Population frequencies: Poor metabolizers ~7% of Caucasians; varies by ethnicity.
• Effect on atomoxetine levels: Poor metabolizers have 10-fold higher serum levels at same dose.

Implications for poor metabolizers:

• Higher side effect risk at standard doses.
• Lower effective dose: May reach therapeutic effect at 40 mg or less.
• Slower titration recommended: Smaller dose increments, longer adaptation periods.
• Maximum dose lower: 80 mg may be maximum effective; 100 mg may be excessive.
• Pharmacist consultation valuable for genetic considerations.

Drug-induced CYP2D6 inhibition (similar to poor metabolizer status):

• Strong CYP2D6 inhibitors raise atomoxetine levels significantly:
  • Fluoxetine (Prozac) — most common
  • Paroxetine (Paxil)
  • Bupropion (Wellbutrin)
  • Quinidine
  • CBD (cannabidiol) — increasingly relevant
• Atomoxetine dose reduction needed: Often 25% of normal dose.
• Slower titration with strong inhibitors.
• Monitor for excessive side effects.

Genetic testing considerations:

• CYP2D6 genotyping available — increasingly accessible.
• Not routinely required for Strattera initiation in healthy adults.
• Consider testing if:
  • Severe side effects at low doses
  • Family history of medication sensitivity
  • Multiple medications metabolized by CYP2D6
  • Failed prior atomoxetine trial with side effects
• Pharmacogenomics service at some health systems.
• Direct-to-consumer genetic tests (23andMe with pharmacogenomic add-ons).

Pharmacogenomics-informed dosing:

• Poor metabolizer: Start at 20-25 mg; target dose may be 40-60 mg.
• Intermediate metabolizer: Standard or slightly lower starting; target may be 60-80 mg.
• Extensive metabolizer (normal): Standard 40 mg start → 80 mg target.
• Ultra-rapid metabolizer: May need higher doses for effect; 100 mg or sometimes higher.

✨ Bottom Line

The Strattera adult starting dose protocol is 40 mg once daily for 7 days, then titration to 80 mg target dose, with possible increase to 100 mg maximum if 80 mg insufficient. The Day-by-Day Protocol Card provides the 4-week roadmap: Day 1-3 initial exposure with peak side effects, Day 4-7 early adaptation, Day 7 decision point, Day 8-14 therapeutic dose initiation, Day 15-28 stabilization, Day 28-42 full effect assessment.

Why start at 40 mg matters: enables tolerance development to early side effects (nausea, fatigue, dry mouth, headache) before reaching therapeutic dose. Starting at 80 mg directly produces severe initial side effects leading to common patient discontinuation. The 40 mg subtherapeutic period is investment in successful long-term treatment.

Week 1 expectations: side effects begin within hours of first dose, peak days 2-4, diminish by day 7. Day 1-3 most challenging — nausea, fatigue, possible headache, dry mouth. Day 4-5 improvement. Day 6-7 substantial resolution. Take with food, hydrate well, avoid alcohol. No expected ADHD benefit during this phase.

Day 7 titration to 80 mg follows tolerance assessment. Side effects may briefly reappear days 8-10 with dose increase, then resolve. Subtle ADHD benefits may emerge weeks 2-3. Full therapeutic effect takes 4-6 weeks total from starting.

The Dosing Pearl — most "treatment failure" is premature discontinuation during side effect peak (days 2-7) before therapeutic benefits emerge (week 4-6). Patient education about timeline is critical. Survive first 2 weeks of side effects + reach 80 mg therapeutic dose for 4-6 weeks = fair Strattera trial. Stopping during side effect phase is stopping during the worst part.

Side effect watch points across treatment: very common early (nausea, dry mouth, decreased appetite, fatigue, dizziness, insomnia, headache); common throughout (constipation, sexual dysfunction, sweating, heart rate increase, weight loss); less common but serious (liver function abnormalities, suicidal ideation per FDA Black Box, severe cardiovascular events, psychotic symptoms). Specific symptoms warrant immediate prescriber contact.

When to stay at 40 mg longer: severe initial side effects, particularly sensitive patients, CYP2D6 poor metabolizers, concurrent CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion), liver impairment, cardiovascular concerns. Extension typically 1-2 weeks additional; reassess weekly.

Failed titration management: if side effects too severe at 80 mg, return to 40 mg with slower titration or intermediate 60 mg step. If no therapeutic response at 80 mg after 4-6 weeks, consider 100 mg maximum. If still no response, consider Strattera ineffective and explore alternatives (stimulants, Wellbutrin, Intuniv, Qelbree, modafinil).

Four-phase treatment framework provides structure: Phase 1 Initiation (Days 1-7), Phase 2 Titration (Days 8-28), Phase 3 Stabilization (Weeks 4-12), Phase 4 Maintenance (Months 3+). Each phase requires different monitoring focus.

Dosing Decision Tree at Day 7 assesses side effect tolerability, any ADHD benefit signs, special circumstances (CYP2D6 status, inhibitor co-medications, liver function). Action: proceed to 80 mg, stay at 40 mg longer, discontinue, or use lower target dose.

Common starting dose mistakes lead to treatment failure: starting too high (skipping 40 mg phase), titrating too quickly, giving up too early (most common), inadequate dose for body size, ignoring drug interactions (especially MAOIs — absolute contraindication; CYP2D6 inhibitors), wrong dose timing, lack of follow-up during initiation.

CYP2D6 poor metabolizer considerations: ~7% of Caucasians; 10-fold higher serum levels at same dose; lower effective dose (40 mg may suffice); slower titration; maximum dose lower. Strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) produce similar effect; reduce Strattera dose to 25% with strong inhibitors. Genetic testing not routine but consider for severe side effects at low doses or failed prior atomoxetine trials.

For broader Strattera context and other dosing topics, see Strattera and Alcohol, Strattera and Caffeine, Strattera and SSRI/SNRI (CYP2D6 inhibitor context), Strattera and MAOIs (absolute contraindication — washout required before starting), Strattera and Birth Control, Strattera and Marijuana, Strattera and Antihistamines, Strattera and Albuterol, Cardiovascular Effects, Liver Health, FDA Black Box SI, Sleep Effects, Long-Term Side Effects, Weight Loss, Sexual Side Effects, and Withdrawal.

For Strattera comparison cluster: vs Adderall, vs Vyvanse, vs Concerta, vs Ritalin, vs Modafinil, vs Wellbutrin, vs Intuniv, vs Qelbree.

For modafinil as off-label ADHD alternative, Modalert 200 mg from Sun Pharma provides Schedule IV option.

❓ Frequently Asked Questions

📚 References & Further Reading

• FDA prescribing information for Strattera (atomoxetine) — adult dosing protocol.
• American Academy of Family Physicians — ADHD adult treatment guidelines.
• American Psychiatric Association — adult ADHD treatment.
• Clinical Pharmacogenetics Implementation Consortium — CYP2D6 atomoxetine guidelines.
• FDA Pharmacogenomic Biomarkers in Drug Labeling — CYP2D6 atomoxetine.
• National Institute of Mental Health — ADHD adult treatment overview.
• Atomoxetine clinical trial data — efficacy and tolerability studies.
• Strattera lifestyle/interaction cluster: Alcohol, Caffeine, SSRI/SNRI, MAOIs, Birth Control, Marijuana, Antihistamines, Albuterol
• Strattera safety cluster: Long-Term, Cardiovascular, Liver Health, FDA Black Box SI, Sleep, Weight Loss, Sexual Side Effects, Withdrawal
• Strattera comparison cluster: vs Adderall, vs Vyvanse, vs Concerta, vs Ritalin, vs Modafinil, vs Wellbutrin, vs Intuniv, vs Qelbree
• Modalert 200 mg, Modvigil 200 mg, Waklert 150 mg — primary product pages.
• RXshop Editorial Team — content reviewed by licensed pharmacist; for adult patient education, not a substitute for individual medical consultation.